Literature DB >> 30045665

Lack of Benefit on Brain Edema, Blood-Brain Barrier Permeability, or Cognitive Outcome in Global Inducible High Mobility Group Box 1 Knockout Mice Despite Tissue Sparing after Experimental Traumatic Brain Injury.

Rajesh K Aneja1,2, Alicia M Alcamo1,2, Jessica Cummings1,2, Vincent Vagni1, Keri Feldman1, Qingde Wang3, C Edward Dixon4, Timothy R Billiar3, Patrick M Kochanek1.   

Abstract

High mobility group box 1 (HMGB1) is a prototypical danger-associated molecular pattern molecule that is considered a late mediator of neuro-inflammation after traumatic brain injury (TBI). Prior studies have suggested that targeting HMGB1 may lead to neuroprotective effects, but none of these studies have reported cognitive outcomes. We hypothesized that loss of HMGB1 before and after TBI would markedly attenuate post-traumatic brain edema, blood-brain barrier (BBB) permeability, improve functional deficits and long-term neuropathology versus control mice. Using the controlled cortical impact model and conditional global HMGB1 knockout (HMGB1 KO) mice, we demonstrate that there was a neuroprotective effect seen in the HMGB1 KO versus wild-type control evidenced by a significant reduction in contusion volume. However, two surprising findings were 1) the lack of benefit on either post-traumatic brain edema or BBB permeability, and 2) that spatial memory performance was impaired in HMGB1 KO naïve mice such that the behavioral effects of HMGB1 deletion in uninjured naïve mice were similar to those observed after TBI. Our data suggest the possibility that the role of HMGB1 in TBI is a "double-edged sword"; that is, despite the benefits on selected aspects of secondary injury, the sustained absence of HMGB1 may impair cognitive function, even in naïve mice. Given the pleiotropic actions of extracellular and intracellular HMGB1, when evaluating the potential use of therapies targeting HMGB1, effects on long-term cognitive outcome should be carefully evaluated. It also may be prudent in future studies to examine cell-specific effects of manipulating the HMGB1 pathway.

Entities:  

Keywords:  BBB permeability; HMGB1; cognitive impairment; traumatic brain injury

Year:  2018        PMID: 30045665      PMCID: PMC6338570          DOI: 10.1089/neu.2018.5664

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  43 in total

1.  Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS.

Authors:  Hülya Bayir; Valerian E Kagan; Grigory G Borisenko; Yulia Y Tyurina; Keri L Janesko; Vincent A Vagni; Timothy R Billiar; Deborah L Williams; Patrick M Kochanek
Journal:  J Cereb Blood Flow Metab       Date:  2005-06       Impact factor: 6.200

Review 2.  Trauma alarmins as activators of damage-induced inflammation.

Authors:  J Manson; C Thiemermann; K Brohi
Journal:  Br J Surg       Date:  2012-01       Impact factor: 6.939

3.  Transgenic mice that overexpress the anti-apoptotic Bcl-2 protein have improved histological outcome but unchanged behavioral outcome after traumatic brain injury.

Authors:  Roya Tehranian; Marie E Rose; Vincent Vagni; R P Griffith; Shasha Wu; Sara Maits; Xiaopeng Zhang; Robert S B Clark; C Edward Dixon; Patrick M Kochanek; Ora Bernard; Steven H Graham
Journal:  Brain Res       Date:  2006-06-19       Impact factor: 3.252

Review 4.  High-mobility group box 1, oxidative stress, and disease.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Antioxid Redox Signal       Date:  2011-04-01       Impact factor: 8.401

Review 5.  Inflammation and neuroprotection in traumatic brain injury.

Authors:  Kara N Corps; Theodore L Roth; Dorian B McGavern
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

Review 6.  Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease.

Authors:  Yue Zheng; Sarah E Gardner; Murray C H Clarke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-12       Impact factor: 8.311

7.  High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4.

Authors:  Melissa D Laird; Jessica S Shields; Sangeetha Sukumari-Ramesh; Donald E Kimbler; R David Fessler; Basheer Shakir; Patrick Youssef; Nathan Yanasak; John R Vender; Krishnan M Dhandapani
Journal:  Glia       Date:  2013-10-28       Impact factor: 7.452

8.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

9.  Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-κB pathway after traumatic brain injury in the rat.

Authors:  Xingfen Su; Handong Wang; Jinbing Zhao; Hao Pan; Lei Mao
Journal:  Mediators Inflamm       Date:  2011-06-16       Impact factor: 4.711

10.  Wogonin improves histological and functional outcomes, and reduces activation of TLR4/NF-κB signaling after experimental traumatic brain injury.

Authors:  Chien-Cheng Chen; Tai-Ho Hung; Yen-Ho Wang; Chii-Wann Lin; Pei-Yi Wang; Chun-Yen Lee; Szu-Fu Chen
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

View more
  9 in total

1.  The protective effect of uric acid in reducing TLR4/NF-κB activation through the inhibition of HMGB1 acetylation in a model of ischemia-reperfusion injury in vitro.

Authors:  Guan-Mei Cheng; Ruo-Lu Wang; Bin Zhang; Xiao-Ying Deng
Journal:  Mol Biol Rep       Date:  2020-02-24       Impact factor: 2.316

Review 2.  The Role of HMGB1 in Traumatic Brain Injury-Bridging the Gap Between the Laboratory and Clinical Studies.

Authors:  S Manivannan; E Wales; M Zaben
Journal:  Curr Neurol Neurosci Rep       Date:  2021-12-06       Impact factor: 5.081

Review 3.  HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

4.  Regulation of Neurogenesis in Mouse Brain by HMGB1.

Authors:  Xiang Zhao; Ari Rouhiainen; Zhilin Li; Su Guo; Heikki Rauvala
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

5.  Hepatocyte high-mobility group box 1 protects against steatosis and cellular stress during high fat diet feeding.

Authors:  Minjie Lin; Jungke Long; Wenbo Li; Chenxuan Yang; Patricia Loughran; Robert O'Doherty; Timothy R Billiar; Meihong Deng; Melanie J Scott
Journal:  Mol Med       Date:  2020-11-25       Impact factor: 6.354

Review 6.  High Mobility Group Box-1 and Blood-Brain Barrier Disruption.

Authors:  Masahiro Nishibori; Dengli Wang; Daiki Ousaka; Hidenori Wake
Journal:  Cells       Date:  2020-12-10       Impact factor: 6.600

7.  Increase in Blood-Brain Barrier Permeability is Modulated by Tissue Kallikrein via Activation of Bradykinin B1 and B2 Receptor-Mediated Signaling.

Authors:  Qin Zhang; Juan Tan; Li Wan; Chao Chen; Bin Wu; Xijian Ke; Rongxue Wu; Xiao Ran
Journal:  J Inflamm Res       Date:  2021-08-30

8.  Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis.

Authors:  Limin Wu; Joon Yong Chung; Tian Cao; Gina Jin; William J Edmiston; Suzanne Hickman; Emily S Levy; Jordyn A Whalen; Eliza Sophie LaRovere Abrams; Alexei Degterev; Eng H Lo; Lorenzo Tozzi; David L Kaplan; Joseph El Khoury; Michael J Whalen
Journal:  Cell Death Dis       Date:  2021-11-09       Impact factor: 8.469

9.  LPS Primes Brain Responsiveness to High Mobility Group Box-1 Protein.

Authors:  Verena Peek; Lois M Harden; Jelena Damm; Ferial Aslani; Stephan Leisengang; Joachim Roth; Rüdiger Gerstberger; Marita Meurer; Maren von Köckritz-Blickwede; Sabine Schulz; Bernhard Spengler; Christoph Rummel
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.